Three studies recently published simultaneously illustrated synergistic activity of concomitant inhibition of autophagy and MAPK pathway in patient-derived xenografts of KRAS mutant pancreatic ductal adenocarcinoma, NRAS mutant melanoma and B-RAF mutant colorectal tumor [165,166,167]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.